Telavancin (vibativ), a new option for the treatment of gram-positive infections.
作者信息
Plotkin Polina, Patel Khusbu, Uminski Amy, Marzella Nino
出版信息
P T. 2011 Mar;36(3):127-38.
Abstract
摘要
相似文献
1
2
Chemical Stability of Telavancin in Elastomeric Pumps.替考拉宁在弹性泵中的化学稳定性
Curr Ther Res Clin Exp. 2015 Oct 22;77:99-104. doi: 10.1016/j.curtheres.2015.10.002. eCollection 2015 Dec.
3
Telavancin (Vibativ) for gram-positive skin infections.
Med Lett Drugs Ther. 2010 Jan 11;52(1329):1-2.
4
Effect of telavancin (Vibativ) on routine coagulation test results.替考拉宁（威凡）对常规凝血检测结果的影响。
Am J Clin Pathol. 2011 Dec;136(6):848-54. doi: 10.1309/AJCPDPL4G7CERYJU.
5
Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.特拉万星（VIBATIV）用于治疗复杂性皮肤及皮肤结构感染。
Expert Rev Anti Infect Ther. 2015 Jul;13(7):825-33. doi: 10.1586/14787210.2015.1043889. Epub 2015 May 17.
6
Telavancin (Vibativ). A vancomycin derivative, no more effective but more toxic.
Prescrire Int. 2015 Nov;24(165):257-9.
7
Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.替考拉宁作为癌症患者革兰氏阳性血流感染替代治疗的病例对照研究。
Antimicrob Agents Chemother. 2015 Oct 19;60(1):239-44. doi: 10.1128/AAC.00617-15. Print 2016 Jan.
8
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.替拉万星治疗医院获得性肺炎临床试验：革兰氏阴性菌感染和革兰氏阴性菌覆盖不充分对临床疗效和全因死亡率的影响。
Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S87-93. doi: 10.1093/cid/civ536.
9
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.特拉万星：一种用于治疗严重革兰氏阳性菌感染的新型脂糖肽。
Expert Opin Investig Drugs. 2007 Mar;16(3):347-57. doi: 10.1517/13543784.16.3.347.
10
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.替加环素对从皮肤及皮肤结构感染患者中分离出的革兰氏阳性菌的活性。
J Chemother. 2010 Oct;22(5):304-11. doi: 10.1179/joc.2010.22.5.304.
引用本文的文献
1
Cyclic peptide drugs approved in the last two decades (2001-2021).在过去二十年（2001年至2021年）获批的环肽药物。
RSC Chem Biol. 2021 Nov 5;3(1):18-31. doi: 10.1039/d1cb00154j. eCollection 2022 Jan 5.
2
Alternatives to Fight Vancomycin-Resistant and .对抗耐万古霉素的替代方法及…… （原文不完整，翻译可能不太准确）
Antibiotics (Basel). 2021 Sep 16;10(9):1116. doi: 10.3390/antibiotics10091116.
3
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.特拉万星：一种新型半合成脂糖肽类药物，用于应对耐革兰氏阳性病原体的挑战。
Ther Adv Infect Dis. 2017 Mar;4(2):49-73. doi: 10.1177/2049936117690501. Epub 2017 Mar 8.
4
Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.替考拉宁单独及与氨苄西林联合治疗粪肠球菌心内膜炎大鼠模型的疗效
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02489-16. Print 2017 Jun.
5
Update on the emerging role of telavancin in hospital-acquired infections.特拉万星在医院获得性感染中新兴作用的最新进展。
Ther Clin Risk Manag. 2015 Apr 13;11:605-10. doi: 10.2147/TCRM.S57376. eCollection 2015.
6
Quantitative determination of telavancin in pregnant baboon plasma by solid-phase extraction and LC-ESI-MS.通过固相萃取和液相色谱-电喷雾电离质谱法对怀孕狒狒血浆中的替拉万星进行定量测定。
J Pharm Biomed Anal. 2014 Sep;98:107-12. doi: 10.1016/j.jpba.2014.04.030. Epub 2014 May 2.
7
Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.用于治疗婴儿、儿童和成人耐甲氧西林金黄色葡萄球菌感染的近期批准药物的药代动力学和安全性。
Expert Rev Clin Pharmacol. 2014 May;7(3):327-40. doi: 10.1586/17512433.2014.909281. Epub 2014 Apr 9.
本文引用的文献
1
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.替拉万星在感染的体外药代动力学模型中的药效学研究。
Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.
2
Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women.老年男性和女性患者中单剂替考拉宁的药代动力学和耐受性。
Pharmacotherapy. 2010 Aug;30(8):806-11. doi: 10.1592/phco.30.8.806.
3
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.新型糖肽类抗生素：达巴万星、奥他万星和替拉万星的比较综述。
Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000.
4
Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.替拉万星对细胞色素 P450 3A 探针底物咪达唑仑药代动力学的影响：一项在健康受试者中进行的随机、双盲、交叉研究。
Pharmacotherapy. 2010 Feb;30(2):136-43. doi: 10.1592/phco.30.2.136.
5
Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.中度肝功能损害对替拉凡星药代动力学的影响。
Pharmacotherapy. 2010 Jan;30(1):35-42. doi: 10.1592/phco.30.1.35.
6
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.在健康受试者中，替加环素与氨曲南或哌拉西林/他唑巴坦联合给药后缺乏药代动力学药物相互作用。
J Clin Pharmacol. 2009 Jul;49(7):816-23. doi: 10.1177/0091270009337133. Epub 2009 May 14.
7
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.健康男性和女性受试者静脉注射替拉万星的多剂量药代动力学
J Antimicrob Chemother. 2008 Oct;62(4):780-3. doi: 10.1093/jac/dkn273. Epub 2008 Jun 26.
8
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.替考拉宁与万古霉素治疗革兰氏阳性菌引起的复杂性皮肤及皮肤结构感染的比较
Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896.
9
Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.通过群体药代动力学建模和蒙特卡洛模拟确定替拉万星在人上皮衬液中的渗透情况。
Antimicrob Agents Chemother. 2008 Jul;52(7):2300-4. doi: 10.1128/AAC.01110-07. Epub 2008 Apr 21.
10
Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.替考拉宁静脉给药在健康受试者体内的肺内分布以及肺表面活性物质对替考拉宁和其他抗生素体外活性的影响。
Antimicrob Agents Chemother. 2008 Jan;52(1):92-7. doi: 10.1128/AAC.00875-07. Epub 2007 Oct 8.
Zotero 插件